|drug51||38 questions questionnaire Wiki||1.00|
|drug1126||EPDS (Edinburgh Postnatal Depression Scale) Wiki||1.00|
|drug1350||GAD-7 (General Anxiety Disorder) scale Wiki||1.00|
|D019052||Depression, Postpartum NIH||0.38|
|D003866||Depressive Disorder NIH||0.20|
|D013315||Stress, Psychological NIH||0.18|
There is one clinical trial.
The necessity for early detection and hence improving the outcome of treatment of pneumonia is critical especially SARS-CoV-2 induced cases. This work was designed to evaluate the potential application of measuring circulating epigenetic markers namely, miR-744, miR-24, miR-124, miR-155, miR-19a, miR-122, miR-21, miR-223, let-7f, miR-146, miR-196, miR-136, P13-K, miR-9 expression, and DNA methylation profiling of the ACE2, TMPRSS2, PARP, HOX1 genes in Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 with/without pneumonia and severe acute respiratory syndrome (SARS) patients as an attempt to evaluate the potential benefits of these new circulating, prognostic, epigenetic markers for Turkish patients.
Description: Analysis of pathway-related micro RNAs in patients with mild, moderate and severe Covid 19 clinicsMeasure: Determination of the relationship between the severity of disease and epigenetic factors in COVID 19 Time: Seven months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports